Loading...
•
Mar 31, 2025
Boston Scientific Q1 2025 Earnings Report
Boston Scientific posted strong Q1 2025 results with notable revenue and earnings growth driven by its cardiovascular segment and U.S. market expansion.
Key Takeaways
Boston Scientific delivered an impressive start to the year with $4.66 billion in revenue, a 20.9% increase year-over-year. Net income rose to $674 million, while adjusted EPS reached $0.75. The cardiovascular segment led performance with 25.6% organic growth, and U.S. sales jumped over 30%.
Total revenue increased 20.9% year-over-year to $4.66 billion
Net income rose to $674 million, up from $495 million the prior year
Adjusted EPS reached $0.75, beating guidance
Cardiovascular segment and U.S. sales were key growth drivers
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Boston Scientific expects continued revenue and earnings growth in Q2 and full-year 2025, driven by operational execution and innovation, despite potential macroeconomic and supply chain risks.
Positive Outlook
- Q2 2025 reported revenue growth projected at 17.5–19.5%
- Full-year reported revenue growth projected at 15–17%
- Q2 adjusted EPS forecasted at $0.71–$0.73
- Strong pipeline of clinical trials and product innovation
- Operational and organic growth targets raised across segments
Challenges Ahead
- Impact of foreign currency expected to remain neutral in Q2
- Acquisition/divestiture-related impacts reduce organic growth comparability
- Global macroeconomic uncertainty persists
- Supply chain pressures could continue
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...